Qiagen (QGEN) Given “Buy” Rating at Commerzbank

Qiagen (NASDAQ:QGEN)‘s stock had its “buy” rating reissued by Commerzbank in a research note issued on Friday.

Several other equities research analysts have also recently issued reports on QGEN. Cowen restated a “hold” rating and issued a $33.00 target price on shares of Qiagen in a report on Thursday, September 28th. BidaskClub cut shares of Qiagen from a “hold” rating to a “sell” rating in a report on Friday, December 29th. Evercore ISI assumed coverage on shares of Qiagen in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Finally, TheStreet upgraded shares of Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Qiagen currently has an average rating of “Hold” and a consensus price target of $34.63.

Shares of Qiagen (NASDAQ:QGEN) traded up $0.31 on Friday, hitting $32.87. 1,831,029 shares of the company traded hands, compared to its average volume of 1,010,000. The company has a market capitalization of $7,520.00, a P/E ratio of 84.28, a P/E/G ratio of 1.81 and a beta of 1.10. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68. Qiagen has a 12 month low of $27.51 and a 12 month high of $36.34.

Qiagen (NASDAQ:QGEN) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. equities analysts predict that Qiagen will post 1.25 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of QGEN. Atlanta Capital Management Co. L L C boosted its stake in shares of Qiagen by 210.1% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock worth $41,400,000 after acquiring an additional 890,454 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Qiagen during the 2nd quarter worth $26,408,000. WINTON GROUP Ltd purchased a new position in shares of Qiagen during the 2nd quarter worth $15,088,000. Vanguard Group Inc. boosted its stake in shares of Qiagen by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock worth $202,986,000 after acquiring an additional 394,201 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Qiagen by 127.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 652,285 shares of the company’s stock worth $20,521,000 after acquiring an additional 365,732 shares during the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/20/qiagen-qgen-given-buy-rating-at-commerzbank.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply